The results of the Explorer7 trial showed that concizumab – an anti-tissue factor pathway inhibitor (TFPI) antibody – reduced the number of treated bleeds in patients by 86% when given as a ...

The once-weekly anti-TFPI antibody has been cleared by the European Commission for adults and adolescents aged 123 and over with severe haemophilia A or B, without inhibitors, becoming the first ...